A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

Part of paid clinical trials in Walnut Creek, California.

Sponsor
BioNTech SE
Study ID
NCT07730450
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • COVID-19 Vaccines

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • BNT162b2 Vaccine — BIOLOGICAL
    Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.
  • Tdap Vaccine — BIOLOGICAL
    Participants will receive a single injection containing Tdap on Day 1.

Study Details

The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough). The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines. Participants will be in the study for about 12 months.

Key Dates

First listed
Jul 28, 2026
Start date
Jul 23, 2026
Status verified
Jul 2026
Primary completion
Aug 6, 2027
Completion
Aug 6, 2027

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Tdap Vaccine
    Participants will receive a single injection containing Tdap on Day 1.
  • Experimental: BNT162b2 Vaccine
    Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.

Primary Outcome Measure

Percentage of participants reporting local reactions or systemic events [ Time Frame: From Day 1 up to 7 days after Vaccination ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Diablo Clinical Research, LLC dba Flourish ResearchWalnut CreekCalifornia94598-
Palm Springs Community Health CenterMiami LakesFlorida33014-
East-West Medical Research InstituteHonoluluHawaii96814-
J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake CityUtah84109-

Find similar trials in Walnut Creek, CA

By research site
Diablo Clinical Research, LLC dba Flourish Research· Walnut Creek, CAPalm Springs Community Health Center· Miami Lakes, FLEast-West Medical Research Institute· Honolulu, HIJ. Lewis Research, Inc. / Foothill Family Clinic· Salt Lake City, UT